Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Univercells.

    Client Virtual Booth

    UNIVERCELLS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Univercells
    Belgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Rue Auguste Piccard 48 6041 Gosselies, Belgium
    Telephone
    Telephone
    +32 (0)2 318 83 48
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.univercells.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/univercells/
    Twitter
    Twitter
    https://twitter.com/BiologicsforAll

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

    Details:

    Under the terms of the agreement, Univercells will test in vitro and in vivo a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform to prevent, treat, and cure diseases in a range of fields from oncology to infectious diseases.


    Lead Product(s): mRNA-based Vaccine

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Recipient: Altamira Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 25, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine

    Details:

    Partnership will utilize scale-X™ for Codagenix's pipeline including vaccine candidates for SARS-CoV-2 COVI-VAC™, respiratory syncytial virus (CodaVax™-RSV); influenza (CodaVax™-H1N1); dengue virus; and triple negative breast cancer (using a rationally designed virus).


    Lead Product(s): COVI-VAC

    Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC

    Highest Development Status: Phase IProduct Type: Vaccine

    Recipient: Codagenix

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration May 20, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine

    Details:

    Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with Univercells Technologies’ NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.


    Lead Product(s): COVID-19 vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Vaccine

    Recipient: Exyte

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership May 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine

    Details:

    The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.


    Lead Product(s): Adenoviral vector-based vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Vaccine

    Recipient: ReiThera

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 23, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search